Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ON 01910.Na and irinotecan · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| A | EXPERIMENTAL | Treatment of escalating doses of ON 01910.Na in combination with irinotecan |
| B | EXPERIMENTAL | Treatment of escalating doses of ON 01910.Na in combination with oxaliplatin |
| Name | Type | Description |
|---|---|---|
| ON 01910.Na and irinotecan | DRUG | ON 01910.Na will be administered by IV infusion over 24 hours once per week in a 6-week cycle (6 doses per cycle). The dose of ON 01910.Na will start at 250 mg/m2 and will proceed to higher dose levels after safety evaluation. The suggested starting dose of Irinotecan is 180 mg/m2 administered by intravenous (IV) infusion over 90 minutes every 2 weeks of a 6-week cycle (3 doses per cycle). Reductions in the starting doses according to recommendations of current approved prescribing information may be considered after review of patients' medical histories and potential tolerances to treatment with the chemotherapy agent. |
| ON 01910.Na and oxaliplatin | DRUG | ON 01910.Na will be administered by IV infusion over 24 hours once per week in a 6-week cycle (6 doses per cycle). The dose of ON 01910.Na will start at 250 mg/m2 and will proceed to higher dose levels after safety review of the combination regimen in the previous cohort. The suggested starting dose of Oxaliplatin is 85 mg/m2 administered by IV infusion over 120 minutes every 2 weeks of a 6-week cycle (3 doses per cycle). Reductions in the starting doses according to recommendations of current approved prescribing information may be considered after review of patients' medical histories and potential tolerances to treatment with the chemotherapy agent. |
Inclusion Criteria: * Male and female patients ≥18 years of age with histologically or cytologically confirmed solid tumors that are metastatic or progressive, for whom no standard therapy holds curative potential and for whom irinotecan or oxaliplatin are reasonable treatment options. * Patients m...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
ON 01910.Na is an investigational small molecule being studied for the treatment of myelodysplastic syndromes, acute myelocytic leukemia, metastatic pancreatic adenocarcinoma, malignant neoplasms, and advanced solid tumors. It is being developed by Traws Pharma, Inc. for oncology indications.
ON 01910.Na is being developed by Traws Pharma, Inc., a biopharmaceutical company. The company is publicly traded under the ticker symbol TRAW.
ON 01910.Na has completed Phase 1 and Phase 3 clinical trials. It is an investigational drug that has not been approved by the FDA. The completed trials include Phase 1 studies in leukemia and solid tumors, and Phase 3 studies in myelodysplastic syndromes and pancreatic cancer.
ON 01910.Na has been studied in three completed clinical trials. NCT00854646 was a Phase 1 study in refractory leukemia or myelodysplastic syndrome. NCT01125891 was a Phase 1 dose escalation study with gemcitabine in solid tumors. NCT01241500 was a Phase 3 study in refractory myelodysplastic syndrome patients with excess blasts.
ON 01910.Na is also known as rigosertib. It is a small molecule being developed by Traws Pharma, Inc. for oncology indications including myelodysplastic syndromes and pancreatic cancer.